Diagnosis and Management of Clostridium difficile Infection

Abstract

There have been dramatic changes in the epidemiology of Clostridium difficile infection (CDI), with increases in incidence and severity of disease, attributed to the emergence of a fluoroquinolone-resistant “hypervirulent” strain, ribotype 027. C. difficile is now the most common pathogen causing hospital-acquired infection in U.S. hospitals, and community-acquired infections are increasing. The diagnosis of CDI is based on a combination of signs and symptoms, confirmed by laboratory tests. Clinical manifestations of CDI can range from asymptomatic colonization to severe pseudomembranous colitis and death. Many aspects of laboratory diagnosis of CDI remain contentious. Toxin enzyme immunoassays are too insensitive to be used alone, while nucleic acid amplification tests have emerged as an option, either as a stand-alone test or as part of a multitest algorithm. Oral vancomycin and metronidazole have been the recommended antimicrobial therapy options, and fidaxomicin is an effective new alternative. There is ongoing concern regarding the potential inferiority of metronidazole, in particular for severe CDI. Management of severe CDI and recurrent CDI continue to represent major treatment challenges. Biological therapies for the restoration of the intestinal microbiota (e.g., fecal microbiota transplantation) and monoclonal antibody therapy are promising approaches for CDI management, in particular troublesome recurrent CDI. This review will concentrate on the diagnosis and management of CDI in adults.

Keywords

Clostridium difficile - antibiotic-associated colitis - pseudomembranous colitis - fecal microbiota transplantation - fidaxomicin - toxic megacolcon

• References

• 1 Young VB, Hanna PC. Overlapping roles for toxins in Clostridium difficile infection. J Infect Dis 2014; 209 (1) 9-11
• 2 Lyras D, O'Connor JR, Howarth PM , et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458 (7242) 1176-1179
• 3 Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010; 467 (7316) 711-713
• 4 Kuehne SA, Collery MM, Kelly ML, Cartman ST, Cockayne A, Minton NP. Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain. J Infect Dis 2014; 209 (1) 83-86
• 5 Freeman J, Bauer MP, Baines SD , et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23 (3) 529-549
• 6 Pépin J, Valiquette L, Alary M-E , et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171 (5) 466-472
• 7 Loo VG, Bourgault A-M, Poirier L , et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365 (18) 1693-1703
• 8 McDonald LC, Killgore GE, Thompson A , et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353 (23) 2433-2441
• 9 Warny M, Pepin J, Fang A , et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366 (9491) 1079-1084
• 10 Carter GP, Douce GR, Govind R , et al. The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog 2011; 7 (10) e1002317
• 11 Magill SS, Edwards JR, Bamberg W , et al; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370 (13) 1198-1208
• 12 Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011; 32 (4) 387-390
• 13 Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States; 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/
• 14 Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012; 55 (Suppl. 02) S88-S92
• 15 Hensgens MPM, Keessen EC, Squire MM , et al; European Society of Clinical Microbiology and Infectious Diseases Study Group for Clostridium difficile (ESGCD). Clostridium difficile infection in the community: a zoonotic disease?. Clin Microbiol Infect 2012; 18 (7) 635-645
• 16 Khanna S, Pardi DS, Aronson SL , et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2012; 107 (1) 89-95
• 17 Khanna S, Pardi DS. Community-acquired Clostridium difficile infection: an emerging entity. Clin Infect Dis 2012; 55 (12) 1741-1742
• 18 Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012; 55 (Suppl. 02) S65-S70
• 19 Lessa FC. Community-associated Clostridium difficile infection: how real is it?. Anaerobe 2013; 24: 121-123
• 20 Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014; 69 (4) 881-891
• 21 Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 2013; 57 (5) 2326-2332
• 22 Deshpande A, Pasupuleti V, Thota P , et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013; 68 (9) 1951-1961
• 23 Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 2014; 146 (6) 1547-1553
• 24 Hensgens MPM, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 2012; 67 (3) 742-748
• 25 Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107 (7) 1001-1010
• 26 Vonberg R-P, Kuijper EJ, Wilcox MH , et al; European C difficile-Infection Control Group; European Centre for Disease Prevention and Control (ECDC). Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008; 14 (Suppl. 05) 2-20
• 27 Dubberke ER, Carling P, Carrico R , et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 Update. Infect Control Hosp Epidemiol 2014; 35 (6) 628-645
• 28 Edmonds SL, Zapka C, Kasper D , et al. Effectiveness of hand hygiene for removal of Clostridium difficile spores from hands. Infect Control Hosp Epidemiol 2013; 34 (3) 302-305
• 29 McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320 (4) 204-210
• 30 Weber DJ, Anderson DJ, Sexton DJ, Rutala WA. Role of the environment in the transmission of Clostridium difficile in health care facilities. Am J Infect Control 2013; 41 (5, Suppl): S105-S110
• 31 Wilcox MH, Fraise AP, Bradley CR, Walker J, Finch RG. Sporicides for Clostridium difficile: the devil is in the detail. J Hosp Infect 2011; 77 (3) 187-188
• 32 Feazel LM, Malhotra A, Perencevich EN, Kaboli P, Diekema DJ, Schweizer ML. Effect of antibiotic stewardship programmes on Clostridium difficile incidence: a systematic review and meta-analysis. J Antimicrob Chemother 2014; 69 (7) 1748-1754
• 33 Wilcox MH, Shetty N, Fawley WN , et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin Infect Dis 2012; 55 (8) 1056-1063
• 34 Debast SB, Bauer MP, Kuijper EJ ; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20 (Suppl. 02) 1-26
• 35 Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346 (5) 334-339
• 36 Kelly CP, LaMont JT. Clostridium difficile—more difficult than ever. N Engl J Med 2008; 359 (18) 1932-1940
• 37 Walker AS, Eyre DW, Wyllie DH , et al; Infections in Oxfordshire Research Database. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis 2013; 56 (11) 1589-1600
• 38 Aronoff DM. Editorial commentary: host-pathogen interactions in Clostridium difficile infection: it takes two to tango. Clin Infect Dis 2014; 58 (10) 1401-1403
• 39 Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342 (6) 390-397
• 40 Alasmari F, Seiler SM, Hink T, Burnham C-AD, Dubberke ER. Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin Infect Dis 2014; 59 (2) 216-222
• 41 Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RLP, Donskey CJ. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007; 45 (8) 992-998
• 42 Curry SR, Muto CA, Schlackman JL , et al. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis 2013; 57 (8) 1094-1102
• 43 Burnham C-AD, Carroll KC. Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev 2013; 26 (3) 604-630
• 44 Crobach MJT, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009; 15 (12) 1053-1066
• 45 Brecher SM, Novak-Weekley SM, Nagy E. Laboratory diagnosis of Clostridium difficile infections: there is light at the end of the colon. Clin Infect Dis 2013; 57 (8) 1175-1181
• 46 Ticehurst JR, Aird DZ, Dam LM, Borek AP, Hargrove JT, Carroll KC. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 2006; 44 (3) 1145-1149
• 47 Aichinger E, Schleck CD, Harmsen WS, Nyre LM, Patel R. Nonutility of repeat laboratory testing for detection of Clostridium difficile by use of PCR or enzyme immunoassay. J Clin Microbiol 2008; 46 (11) 3795-3797
• 48 Luo RF, Banaei N. Is repeat PCR needed for diagnosis of Clostridium difficile infection?. J Clin Microbiol 2010; 48 (10) 3738-3741
• 49 Cohen SH, Gerding DN, Johnson S , et al; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31 (5) 431-455
• 50 Planche T, Wilcox M. Reference assays for Clostridium difficile infection: one or two gold standards?. J Clin Pathol 2011; 64 (1) 1-5
• 51 Eastwood K, Else P, Charlett A, Wilcox M. Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol 2009; 47 (10) 3211-3217
• 52 Carroll KC. Tests for the diagnosis of Clostridium difficile infection: the next generation. Anaerobe 2011; 17 (4) 170-174
• 53 Planche TD, Davies KA, Coen PG , et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis 2013; 13 (11) 936-945
• 54 Goldenberg SD, Gumban M, Hall A, Patel A, French GL. Lack of effect of strain type on detection of toxigenic Clostridium difficile by glutamate dehydrogenase and polymerase chain reaction. Diagn Microbiol Infect Dis 2011; 70 (3) 417-419
• 55 Carman RJ, Wickham KN, Chen L , et al. Glutamate dehydrogenase is highly conserved among Clostridium difficile ribotypes. J Clin Microbiol 2012; 50 (4) 1425-1426
• 56 Shetty N, Wren MWD, Coen PG. The role of glutamate dehydrogenase for the detection of Clostridium difficile in faecal samples: a meta-analysis. J Hosp Infect 2011; 77 (1) 1-6
• 57 Novak-Weekley SM, Marlowe EM, Miller JM , et al. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J Clin Microbiol 2010; 48 (3) 889-893
• 58 Kok J, Wang Q, Thomas LC, Gilbert GL. Presumptive identification of Clostridium difficile strain 027/NAP1/BI on Cepheid Xpert: interpret with caution. J Clin Microbiol 2011; 49 (10) 3719-3721
• 59 Lim SK, Stuart RL, Mackin KE , et al. Emergence of a ribotype 244 strain of Clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain. Clin Infect Dis 2014; 58 (12) 1723-1730
• 60 Deshpande A, Pasupuleti V, Rolston DDK , et al. Diagnostic accuracy of real-time polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile Infection: a meta-analysis. Clin Infect Dis 2011; 53 (7) e81-e90
• 61 Wilcox MH, Planche T, Fang FC, Gilligan P. What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection?. J Clin Microbiol 2010; 48 (12) 4347-4353
• 62 Surawicz CM, Brandt LJ, Binion DG , et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108 (4) 478-498 , quiz 499
• 63 Longtin Y, Trottier S, Brochu G , et al. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin Infect Dis 2013; 56 (1) 67-73
• 64 Goldenberg SD, Price NM, Tucker D, Wade P, French GL. Mandatory reporting and improvements in diagnosing Clostridium difficile infection: an incompatible dichotomy?. J Infect 2011; 62 (5) 363-370
• 65 Gould CV, Edwards JR, Cohen J , et al; Clostridium difficile Infection Surveillance Investigators, Centers for Disease Control and Prevention. Effect of nucleic acid amplification testing on population-based incidence rates of Clostridium difficile infection. Clin Infect Dis 2013; 57 (9) 1304-1307
• 66 Larson AM, Fung AM, Fang FC. Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J Clin Microbiol 2010; 48 (1) 124-130
• 67 Babady NE, Stiles J, Ruggiero P , et al. Evaluation of the Cepheid Xpert Clostridium difficile Epi assay for diagnosis of Clostridium difficile infection and typing of the NAP1 strain at a cancer hospital. J Clin Microbiol 2010; 48 (12) 4519-4524
• 68 Tedesco FJ. Antibiotic associated pseudomembranous colitis with negative proctosigmoidoscopy examination. Gastroenterology 1979; 77 (2) 295-297
• 69 Tedesco FJ, Corless JK, Brownstein RE. Rectal sparing in antibiotic-associated pseudomembranous colitis: a prospective study. Gastroenterology 1982; 83 (6) 1259-1260
• 70 Johal SS, Hammond J, Solomon K, James PD, Mahida YR. Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut 2004; 53 (5) 673-677
• 71 Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993; 269 (1) 71-75
• 72 Froberg MK, Palavecino E, Dykoski R, Gerding DN, Peterson LR, Johnson S. Staphylococcus aureus and Clostridium difficile cause distinct pseudomembranous intestinal diseases. Clin Infect Dis 2004; 39 (5) 747-750
• 73 Price AB, Davies DR. Pseudomembranous colitis. J Clin Pathol 1977; 30 (1) 1-12
• 74 Gerding DN, Olson MM, Peterson LR , et al. Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med 1986; 146 (1) 95-100
• 75 Ananthakrishnan AN, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2010; 4 (5) 589-600
• 76 Goodhand JR, Alazawi W, Rampton DS. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33 (4) 428-441
• 77 Kawamoto S, Horton KM, Fishman EK. Pseudomembranous colitis: spectrum of imaging findings with clinical and pathologic correlation. Radiographics 1999; 19 (4) 887-897
• 78 Sheth SG, LaMont JT. Toxic megacolon. Lancet 1998; 351 (9101) 509-513
• 79 Valiquette L, Pépin J, Do X-V , et al. Prediction of complicated Clostridium difficile infection by pleural effusion and increased wall thickness on computed tomography. Clin Infect Dis 2009; 49 (4) 554-560
• 80 Boland GW, Lee MJ, Cats A, Mueller PR. Pseudomembranous colitis: diagnostic sensitivity of the abdominal plain radiograph. Clin Radiol 1994; 49 (7) 473-475
• 81 Boland GW, Lee MJ, Cats AM, Gaa JA, Saini S, Mueller PR. Antibiotic-induced diarrhea: specificity of abdominal CT for the diagnosis of Clostridium difficile disease. Radiology 1994; 191 (1) 103-106
• 82 Ash L, Baker ME, O'Malley Jr CM, Gordon SM, Delaney CP, Obuchowski NA. Colonic abnormalities on CT in adult hospitalized patients with Clostridium difficile colitis: prevalence and significance of findings. AJR Am J Roentgenol 2006; 186 (5) 1393-1400
• 83 Kirkpatrick ID, Greenberg HM. Evaluating the CT diagnosis of Clostridium difficile colitis: should CT guide therapy?. AJR Am J Roentgenol 2001; 176 (3) 635-639
• 84 Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008; 70 (4) 298-304
• 85 Mullane KM, Miller MA, Weiss K , et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53 (5) 440-447 (Erratum in Clin Infect Dis. 2011;53(12):1312)
• 86 Teasley DG, Gerding DN, Olson MM , et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2 (8358) 1043-1046
• 87 Koo HL, Koo DC, Musher DM, DuPont HL. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis 2009; 48 (5) 598-605
• 88 Chaparro-Rojas F, Mullane KM. Emerging therapies for Clostridium difficile infection—focus on fidaxomicin. Infect Drug Resist 2013; 6: 41-53
• 89 Gerding DN. Metronidazole for Clostridium difficile-associated disease: is it okay for Mom?. Clin Infect Dis 2005; 40 (11) 1598-1600
• 90 Drekonja DM, Butler M, MacDonald R , et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med 2011; 155 (12) 839-847
• 91 Nelson RL, Kelsey P, Leeman H , et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2011; (9) CD004610 . doi: 10.1002/14651858.CD004610.pub4
• 92 Wilcox MH. Editorial Commentary: the trials and tribulations of treating Clostridium difficile infection-one step backward, one step forward, but still progress. Clin Infect Dis 2014; 59 (3) 355-357
• 93 Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46 (10) 1489-1492
• 94 Tran M-CN, Claros MC, Goldstein EJC. Therapy of Clostridium difficile infection: perspectives on a changing paradigm. Expert Opin Pharmacother 2013; 14 (17) 2375-2386
• 95 Musher DM, Aslam S, Logan N , et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40 (11) 1586-1590
• 96 Pepin J, Alary M-E, Valiquette L , et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40 (11) 1591-1597
• 97 Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RLP, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47 (1) 56-62
• 98 Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45 (3) 302-307
• 99 Modena S, Gollamudi S, Friedenberg F. Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2006; 40 (1) 49-54
• 100 Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995; 36 (4) 673-679
• 101 Johnson S, Louie TJ, Gerding DN , et al; Polymer Alternative for CDI Treatment (PACT) investigators. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014; 59 (3) 345-354
• 102 Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27 (10) 1169-1172
• 103 Johnson S, Homann SR, Bettin KM , et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992; 117 (4) 297-302
• 104 Baines SD, O'Connor R, Freeman J , et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62 (5) 1046-1052
• 105 Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 51 (8) 2716-2719
• 106 Sears P, Crook DW, Louie TJ, Miller MA, Weiss K. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis 2012; 55 (Suppl. 02) S116-S120
• 107 Weiss K, Allgren RL, Sellers S. Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections. Clin Infect Dis 2012; 55 (Suppl. 02) S110-S115
• 108 Louie TJ, Miller MA, Mullane KM , et al; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364 (5) 422-431
• 109 Cornely OA, Crook DW, Esposito R , et al; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12 (4) 281-289
• 110 Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IAO. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother 2014; 69 (11) 2892-2900
• 111 Petrella LA, Sambol SP, Cheknis A , et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 2012; 55 (3) 351-357
• 112 Babakhani F, Bouillaut L, Sears P, Sims C, Gomez A, Sonenshein AL. Fidaxomicin inhibits toxin production in Clostridium difficile. J Antimicrob Chemother 2013; 68 (3) 515-522
• 113 Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis 2012; 55 (Suppl. 02) S162-S169
• 114 Tannock GW, Munro K, Taylor C , et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010; 156 (Pt 11) 3354-3359
• 115 Louie TJ, Cannon K, Byrne B , et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012; 55 (Suppl. 02) S132-S142
• 116 Louie TJ, Emery J, Krulicki W, Byrne B, Mah M. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009; 53 (1) 261-263
• 117 Eyre DW, Babakhani F, Griffiths D , et al. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile. J Infect Dis 2014; 209 (9) 1446-1451
• 118 Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 2012; 55 (Suppl. 02) S121-S126
• 119 Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis 2013; 57 (4) 555-561
• 120 Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IAO. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother 2014; 69 (11) 2901-2912
• 121 Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009; 48 (4) e41-e46
• 122 Zucca M, Scutera S, Savoia D. Novel avenues for Clostridium difficile infection drug discovery. Expert Opin Drug Discov 2013; 8 (4) 459-477
• 123 Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS ONE 2014; 9 (6) e98400
• 124 Bauer MP, Hensgens MPM, Miller MA , et al. Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis. Clin Infect Dis 2012; 55 (Suppl. 02) S149-S153
• 125 Miller MA, Louie T, Mullane K , et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis 2013; 13: 148
• 126 Abou Chakra CN, Pepin J, Valiquette L. Prediction tools for unfavourable outcomes in Clostridium difficile infection: a systematic review. PLoS ONE 2012; 7 (1) e30258
• 127 Goorhuis A, Bakker D, Corver J , et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008; 47 (9) 1162-1170
• 128 Miller M, Gravel D, Mulvey M , et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010; 50 (2) 194-201
• 129 Gerding DN, Johnson S. Does infection with specific Clostridium difficile strains or clades influence clinical outcome?. Clin Infect Dis 2013; 56 (11) 1601-1603
• 130 Walk ST, Micic D, Galecki AT, Young VB, Aronoff DM. Understanding increased mortality in Clostridium difficile-infected older adults. Clin Infect Dis 2013; 57 (4) 625-626
• 131 See I, Mu Y, Cohen J , et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis 2014; 58 (10) 1394-1400
• 132 Johnson S. Editorial commentary: changing epidemiology of Clostridium difficile and emergence of new virulent strains. Clin Infect Dis 2014; 58 (12) 1731-1733
• 133 Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86 (1) 15-19
• 134 Friedenberg F, Fernandez A, Kaul V, Niami P, Levine GM. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum 2001; 44 (8) 1176-1180
• 135 Bass SN, Bauer SR, Neuner EA, Lam SW. Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection. J Hosp Infect 2013; 85 (1) 22-27
• 136 Wenisch JM, Schmid D, Kuo H-W , et al. Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection. Antimicrob Agents Chemother 2012; 56 (4) 1974-1978
• 137 Tedesco F, Markham R, Gurwith M, Christie D, Bartlett JG. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 1978; 2 (8083) 226-228
• 138 Aldape MJ, Heeney DD, Bryant AE, Stevens DL. Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile. J Antimicrob Chemother 2015; 70: 153-159
• 139 Nord CE, Sillerström E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006; 50 (10) 3375-3380
• 140 Jump RLP, Li Y, Pultz MJ, Kypriotakis G, Donskey CJ. Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production. Antimicrob Agents Chemother 2011; 55 (2) 546-549
• 141 Herpers BL, Vlaminckx B, Burkhardt O , et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009; 48 (12) 1732-1735
• 142 Thomas A, Khan F, Uddin N, Wallace MR. Tigecycline for severe Clostridium difficile infection. Int J Infect Dis 2014; 26: 171-172
• 143 Cheong EYL, Gottlieb T. Intravenous tigecycline in the treatment of severe recurrent Clostridium difficile colitis. Med J Aust 2011; 194 (7) 374-375
• 144 Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002; 35 (6) 690-696
• 145 Kim PK, Huh HC, Cohen HW , et al. Intracolonic vancomycin for severe Clostridium difficile colitis. Surg Infect (Larchmt) 2013; 14 (6) 532-539
• 146 Saffouri G, Khanna S, Estes L, Pardi D. Outcomes from rectal vancomycin therapy in patients with Clostridium difficile infection. Am J Gastroenterol 2014; 109 (6) 924-925
• 147 Bhangu A, Nepogodiev D, Gupta A, Torrance A, Singh P ; West Midlands Research Collaborative. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg 2012; 99 (11) 1501-1513
• 148 Lamontagne F, Labbé A-C, Haeck O , et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007; 245 (2) 267-272
• 149 Stewart DB, Hollenbeak CS, Wilson MZ. Is colectomy for fulminant Clostridium difficile colitis life saving? A systematic review. Colorectal Dis 2013; 15 (7) 798-804
• 150 Noblett SE, Welfare M, Seymour K. The role of surgery in Clostridium difficile colitis. BMJ 2009; 338: b1563
• 151 Karmali S, Laffin M, de Gara C. CAGS Clinical Practice Committee report: the science of Clostridium difficile and surgery. Can J Surg 2013; 56 (6) 367-371
• 152 Ferrada P, Velopulos CG, Sultan S , et al. Timing and type of surgical treatment of Clostridium difficile-associated disease: a practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg 2014; 76 (6) 1484-1493
• 153 Sailhamer EA, Carson K, Chang Y , et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 2009; 144 (5) 433-439 , discussion 439–440
• 154 Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011; 254 (3) 423-427 , discussion 427–429
• 155 Brown CJ, Boutros M, Morris A, Divino CM ; CAGS/ACS Evidence Based Reviews in Surgery Group. CAGS and ACS evidence based reviews in surgery. Is a diverting loop ileostomy and colonic lavage an alternative to colectomy for the treatment of severe Clostridium difficile-associated disease?. Can J Surg 2014; 57 (3) 214-216
• 156 McFarland LV, Surawicz CM, Greenberg RN , et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271 (24) 1913-1918
• 157 McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97 (7) 1769-1775
• 158 Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012; 55 (Suppl. 02) S154-S161
• 159 Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985; 80 (11) 867-868
• 160 Johnson S, Gerding DN. Fidaxomicin “chaser” regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Clin Infect Dis 2013; 56 (2) 309-310
• 161 Ojaimi S, Korman TM, Rifaximin. In: Grayson M, Crowe S, McCarthy J. , et al, eds. Kucers' the Use of Antibiotics: American Society for Microbiology and Hodder Arnold; 2010
• 162 Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44 (6) 846-848
• 163 Garey KW, Jiang ZD, Bellard A, Dupont HL. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol 2009; 43 (1) 91-93
• 164 Rubin DT, Sohi S, Glathar M, Thomas T, Yadron N, Surma BL. Rifaximin is effective for the treatment of Clostridium difficile-associated diarrhea: results of an open-label pilot study. Gastroenterol Res Pract 2011; 2011: 106978
• 165 Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila V-J. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2013; 37 (1) 122-128
• 166 Garey KW, Ghantoji SS, Shah DN , et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011; 66 (12) 2850-2855
• 167 O'Connor JR, Galang MA, Sambol SP , et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 2008; 52 (8) 2813-2817
• 168 Curry SR, Marsh JW, Shutt KA , et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009; 48 (4) 425-429
• 169 Huang JS, Jiang ZD, Garey KW, Lasco T, Dupont HL. Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother 2013; 57 (6) 2690-2693
• 170 Miller MA, Blanchette R, Spigaglia P, Barbanti F, Mastrantonio P. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J Clin Microbiol 2011; 49 (12) 4319-4321
• 171 Schubert AM, Rogers MAM, Ring C , et al. Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls. MBio 2014; 5 (3) e01021-e14
• 172 Chang JY, Antonopoulos DA, Kalra A , et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197 (3) 435-438
• 173 Martin J, Mawer D, Wilcox MH. Clostridium difficile: biological therapies. Curr Opin Infect Dis 2013; 26 (5) 454-460
• 174 Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998; 351 (9103) 633-636
• 175 Seal D, Borriello SP, Barclay F, Welch A, Piper M, Bonnycastle M. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol 1987; 6 (1) 51-53
• 176 Villano SA, Seiberling M, Tatarowicz W, Monnot-Chase E, Gerding DN. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother 2012; 56 (10) 5224-5229
• 177 Villano SA, Armstrong J, Meyer T , et al. Therapeutic Use of an Oral Suspension of VP20621, Spores of a Non-Toxigenic Clostridium difficile (NTCD) Strain, for Prevention of Recurrence of C. difficile Infection (CDI). ID Week 2013. Late Breaker Oral Abstracts LB-7. September 28, 2013:169b
• 178 Miller M. The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy. Anaerobe 2009; 15 (6) 281-284
• 179 Tasteyre A, Barc M-C, Karjalainen T, Bourlioux P, Collignon A. Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microb Pathog 2002; 32 (5) 219-225
• 180 Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67 (1) 302-307
• 181 Chen X, Kokkotou EG, Mustafa N , et al. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 2006; 281 (34) 24449-24454
• 182 Qamar A, Aboudola S, Warny M , et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001; 69 (4) 2762-2765
• 183 Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008; 1 (1) CD004611
• 184 Goldenberg JZ, Ma SS, Saxton JD , et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013; 5: CD006095
• 185 Johnston BC, Ma SSY, Goldenberg JZ , et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012; 157 (12) 878-888
• 186 Allen SJ, Wareham K, Bradley C , et al. A multicentre randomised controlled trial evaluating lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea in older people admitted to hospital: the PLACIDE study protocol. BMC Infect Dis 2012; 12: 108
• 187 Allen SJ, Wareham K, Wang D , et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013; 382 (9900) 1249-1257
• 188 Brandt LJ. American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol 2013; 108 (2) 177-185
• 189 Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010; 44 (5) 354-360
• 190 Petrof EO, Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology 2014; 146 (6) 1573-1582
• 191 Brandt LJ, Reddy SS. Fecal microbiota transplantation for recurrent clostridium difficile infection. J Clin Gastroenterol 2011; 45 (Suppl): S159-S167
• 192 van Nood E, Speelman P, Kuijper EJ, Keller JJ. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution?. Euro Surveill 2009; 14 (34) 1-6
• 193 Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53 (10) 994-1002
• 194 Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108 (4) 500-508
• 195 Guo B, Harstall C, Louie T, Veldhuyzen van Zanten S, Dieleman LA. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther 2012; 35 (8) 865-875
• 196 Sofi AA, Silverman AL, Khuder S, Garborg K, Westerink JMA, Nawras A. Relationship of symptom duration and fecal bacteriotherapy in Clostridium difficile infection-pooled data analysis and a systematic review. Scand J Gastroenterol 2013; 48 (3) 266-273
• 197 van Nood E, Vrieze A, Nieuwdorp M , et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368 (5) 407-415
• 198 Brandt LJ, Borody TJ, Campbell J. Endoscopic fecal microbiota transplantation: “first-line” treatment for severe clostridium difficile infection?. J Clin Gastroenterol 2011; 45 (8) 655-657
• 199 Trubiano JA, Gardiner B, Kwong JC, Ward P, Testro AG, Charles PGP. Faecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol 2013; 25 (2) 255-257
• 200 Kelly CR, Ihunnah C, Fischer M , et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014; 109 (7) 1065-1071
• 201 Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 2014; 58 (11) 1507-1514
• 202 Food and Drug Administration. Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies. July 2013. Available at: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm361379.htm
• 203 Hecht GA, Blaser MJ, Gordon J , et al. What is the value of a food and drug administration investigational new drug application for fecal microbiota transplantation to treat Clostridium difficile Infection?. Clin Gastroenterol Hepatol 2014; 12 (2) 289-291
• 204 Bakken JS, Borody T, Brandt LJ , et al; Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9 (12) 1044-1049
• 205 Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107 (5) 761-767
• 206 Youngster I, Sauk J, Pindar C , et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 2014; 58 (11) 1515-1522
• 207 Adamu BO, Lawley TD. Bacteriotherapy for the treatment of intestinal dysbiosis caused by Clostridium difficile infection. Curr Opin Microbiol 2013; 16 (5) 596-601
• 208 de Vos WM. Fame and future of faecal transplantations—developing next-generation therapies with synthetic microbiomes. Microb Biotechnol 2013; 6 (4) 316-325
• 209 Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989; 1 (8648) 1156-1160
• 210 Lawley TD, Clare S, Walker AW , et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012; 8 (10) e1002995
• 211 Petrof EO, Gloor GB, Vanner SJ , et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013; 1 (1) 3
• 212 Allen-Vercoe E, Petrof EO. Artificial stool transplantation: progress towards a safer, more effective and acceptable alternative. Expert Rev Gastroenterol Hepatol 2013; 7 (4) 291-293
• 213 Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357 (9251) 189-193
• 214 Bauer MP, Nibbering PH, Poxton IR, Kuijper EJ, van Dissel JT. Humoral immune response as predictor of recurrence in Clostridium difficile infection. Clin Microbiol Infect 2014;
• 215 Abougergi MS, Broor A, Cui W, Jaar BG. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med 2010; 5 (1) E1-E9
• 216 Humphreys DP, Wilcox MH. Antibodies for treatment of Clostridium difficile infection. Clin Vaccine Immunol 2014; 21 (7) 913-923
• 217 Lowy I, Molrine DC, Leav BA , et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362 (3) 197-205
• 218 Leav BA, Blair B, Leney M , et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010; 28 (4) 965-969
• 219 Lee BY, Popovich MJ, Tian Y , et al. The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine 2010; 28 (32) 5245-5253
• 220 Mizrahi A, Collignon A, Péchiné S. Passive and active immunization strategies against Clostridium difficile infections: State of the art. Anaerobe 2014;